NCT03027388View on ClinicalTrials.gov

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 9, 2019

Primary Completion Date

August 15, 2022

Study Completion Date

August 31, 2022

Conditions
Astrocytoma, Grades II, III and IVGlioblastoma MultiformeGiant Cell GlioblastomaGliomaOligodendrogliomas
Interventions
DRUG

LB-100

LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03027388 - Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter